LANCE AUSTEIN: Open Payments
NPI 1366430969 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,462 in 46 payments from 16 companies in 2025. Trend: 2023 $1,619 · 2024 $1,793 · 2025 $1,462
Food & beverage: $1,369Education: $93
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 10 | $241 |
| Incyte Corporation | 2 | $218 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $213 |
| Novo Nordisk Inc | 2 | $135 |
| AstraZeneca Pharmaceuticals LP | 5 | $112 |
| Axsome Therapeutics, Inc. | 4 | $110 |
| Alkermes, Inc. | 3 | $91 |
| Indivior Inc. | 3 | $80 |
| Lundbeck LLC | 2 | $65 |
| PFIZER INC. | 3 | $51 |
Products named: CAPLYTA, MOUNJARO, Jakafi, Wegovy, Auvelity, VIVITROL, SUBLOCADE, BREZTRI.
Industry payments across NY — which companies pay providers there.
